BMS Plans Appeal After Sandoz And Teva Eliminate UK Eliquis Patent
UK Ruling Saw Local Counterpart Of European Apixaban Patent Declared Invalid
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.
